NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice

TerminatedN/A

Sponsor: Novartis Pharmaceuticals

Conditions: Paroxysmal Nocturnal Hemoglobinuria

Countries: Russia

This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Age ≥18 years at the start of iptacopan therapy.
2. The patient is undergoing treatment with iptacopan.
3. The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
4. Provision of written informed consent.

Exclusion Criteria:

1\. Any situations where iptacopan is contraindicated in accordance with the Summary of Product Characteristics.

Locations (5)

Syktyvkar, Komi, Russia
Grozny, Russia
Moscow, Russia
Murmansk, Russia
Yuzhno-Sakhalinsk, Russia